ELV250117P450000
- 65.90
- 0.000.00%
Elevance Health Newsroom
Morgan Stanley Reaffirms Their Hold Rating on Elevance Health (ELV)
Stephens Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $440
Stephens Downgrades Elevance Health to Equalweight From Overweight, Adjusts Price Target to $440 From $520
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $501
Barclays Remains a Buy on Elevance Health (ELV)
Bernstein Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $502
Analysts Conflicted on These Healthcare Names: Elevance Health (ELV), Agilent (A) and Insulet (PODD)
Elevance Health Is Maintained at Buy by Truist Securities
Truist Financial Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $480
Elevance Health Analyst Ratings
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $455
Mizuho Adjusts Price Target on Elevance Health to $455 From $505, Keeps Outperform Rating
The Medical assistance program may come under pressure as Morgan Stanley downgrades Elevance Health (ELV.US).
Morgan Stanley Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $388
Morgan Stanley Sticks to Its Buy Rating for Elevance Health (ELV)
Jefferies Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $458
Wells Fargo Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $483
Wells Fargo Adjusts Price Target on Elevance Health to $483 From $495, Maintains Overweight Rating
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Announces Target Price $505
Elevance Health Is Maintained at Overweight by Wells Fargo